Dr. Anumantha Kanthasamy has been at the forefront in unraveling the cell-signaling mechanisms underlying the pathophysiological of Parkinson’s disease (PD) and in identifying novel biomarkers and therapeutic strategies for PD. His team recently developed a highly sensitive protein-seeding assay (RT-QuIC) to detect ultralow levels of pathologic alpha-synuclein aggregates in biofluids and skin tissue of individuals with PD. Biomarker discovery efforts based on this RT-QuIC assay resulted in collaborative grants funded by the National Institutes of Health, the Department of Defense and The Michael J. Fox Foundation to evaluate misfolded alpha-synuclein as a biomarker for PD in various biometrics. Dr. Kanthasamy has authored more than 200 peer-reviewed research papers and mentored more than 30 PhD students. He served on many NIH review panels and editorial boards and is currently the John H. “Johnny” Isakson Chair and Georgia Research Alliance Eminent Scholar in Parkinson’s Research.